Global Arterial Thrombosis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Arterial Thrombosis treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Astellas Pharma Inc, Bristol-Myers Squibb Company, GLSynthesis Inc, MDI Therapeutics Inc, Oasis Pharmaceuticals LLC and others.
A Significant contribution to the Arterial Thrombosis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Arterial Thrombosis pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Arterial Thrombosis condition and increased access to investments is encouraging growth of Arterial Thrombosis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Arterial Thrombosis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Arterial Thrombosis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Arterial Thrombosis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Arterial Thrombosis. Further, orphan drug status, fast track designation, grants awarded and other special status for Arterial Thrombosis pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Arterial Thrombosis pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Arterial Thrombosis Pipeline candidates-
A Significant contribution to the Arterial Thrombosis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Arterial Thrombosis pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Arterial Thrombosis condition and increased access to investments is encouraging growth of Arterial Thrombosis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Arterial Thrombosis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Arterial Thrombosis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Arterial Thrombosis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Arterial Thrombosis. Further, orphan drug status, fast track designation, grants awarded and other special status for Arterial Thrombosis pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Arterial Thrombosis pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Arterial Thrombosis Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Arterial Thrombosis drugs
- Late phase: Phase 3 and in-approval Arterial Thrombosis drugs
- Company overview
- Snapshot
- Arterial Thrombosis therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Arterial Thrombosis- Disease Overview
2.2 Arterial Thrombosis- Pipeline Snapshot
2.3 Arterial Thrombosis- Pipeline Drugs by Phase
2.4 Arterial Thrombosis- Pipeline Drugs by Company
2.5 Arterial Thrombosis- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Astellas Pharma Inc Arterial Thrombosis Drug Pipeline, H2- 2019
3.2 Bristol-Myers Squibb Company Arterial Thrombosis Drug Pipeline, H2- 2019
3.3 GLSynthesis Inc Arterial Thrombosis Drug Pipeline, H2- 2019
3.4 MDI Therapeutics Inc Arterial Thrombosis Drug Pipeline, H2- 2019
3.5 Oasis Pharmaceuticals LLC Arterial Thrombosis Drug Pipeline, H2- 2019
3.6 Thromboserin Ltd Arterial Thrombosis Drug Pipeline, H2- 2019
3.7 XBiotech Inc Arterial Thrombosis Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Arterial Thrombosis- Phase 1 Drug Details
4.2 Arterial Thrombosis- Phase 1 Drug Overview
4.3 Arterial Thrombosis- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Arterial Thrombosis- Phase 2 Drug Details
5.2 Arterial Thrombosis- Phase 2 Drug Overview
5.3 Arterial Thrombosis- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Arterial Thrombosis- Phase 3 Drug Details
6.2 Arterial Thrombosis- Phase 3 Drug Overview
6.3 Arterial Thrombosis- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Arterial Thrombosis- Pre-clinical Phase Drug Details
7.2 Arterial Thrombosis- Pre-clinical Phase Drug Overview
7.3 Arterial Thrombosis- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Arterial Thrombosis- Disease Overview
2.2 Arterial Thrombosis- Pipeline Snapshot
2.3 Arterial Thrombosis- Pipeline Drugs by Phase
2.4 Arterial Thrombosis- Pipeline Drugs by Company
2.5 Arterial Thrombosis- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Astellas Pharma Inc Arterial Thrombosis Drug Pipeline, H2- 2019
3.2 Bristol-Myers Squibb Company Arterial Thrombosis Drug Pipeline, H2- 2019
3.3 GLSynthesis Inc Arterial Thrombosis Drug Pipeline, H2- 2019
3.4 MDI Therapeutics Inc Arterial Thrombosis Drug Pipeline, H2- 2019
3.5 Oasis Pharmaceuticals LLC Arterial Thrombosis Drug Pipeline, H2- 2019
3.6 Thromboserin Ltd Arterial Thrombosis Drug Pipeline, H2- 2019
3.7 XBiotech Inc Arterial Thrombosis Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Arterial Thrombosis- Phase 1 Drug Details
4.2 Arterial Thrombosis- Phase 1 Drug Overview
4.3 Arterial Thrombosis- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Arterial Thrombosis- Phase 2 Drug Details
5.2 Arterial Thrombosis- Phase 2 Drug Overview
5.3 Arterial Thrombosis- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Arterial Thrombosis- Phase 3 Drug Details
6.2 Arterial Thrombosis- Phase 3 Drug Overview
6.3 Arterial Thrombosis- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Arterial Thrombosis- Pre-clinical Phase Drug Details
7.2 Arterial Thrombosis- Pre-clinical Phase Drug Overview
7.3 Arterial Thrombosis- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
